Selective androgen receptor modulators

1. A compound according to formula I:

wherein:

R x is CN, Cl, Br, NO 2 or R x1 ;

R y is CH 3 , CF 3 or halogen;

R z is H, C 1-3 alkyl, C 1-3 haloalkyl, NO 2 , NH 2 , OMe, halogen or OH; or

R y and R z together form

R x1 is a 5 member heteroaryl, said heteroaryl selected from:

R′ is hydrogen, C 1 -C 2 alkyl, CF 3 , or halogen; or

R x and R y together with the phenyl group to which they are attached form a 5 member aromatic ring selected from:

wherein each R″ is independently hydrogen, CF 3 , or C 1 -C 2 alkyl;

A is a five member heteroaryl selected from

each R a is independently selected from C 1-4 alkyl, wherein said alkyl is optionally substituted with 1-2 substituents independently selected from CN, OH and 5 member heteroaryl; 5-member heteroaryl, CN, —N(R b )C(O)OC 1-6 alkyl, —N(R b )C(O)OPhenyl, wherein said phenyl is optionally substituted with from 1-3 substituents independently selected from CN, halogen, OH, C 1-3 alkyl, and OC 1-3 alkyl; —N(R b )C(O)C 1-6 alkyl, —N(R b )C(O)Phenyl, wherein said phenyl is optionally substituted with from 1-3 substituents selected from CN, halogen, OH, C 1-3 alkyl, and OC 1-3 alkyl; NR b R b′ , C 1-4 haloalkyl, halogen, OH, OC 1-3 alkyl, OC 1-3 haloalkyl, OSO 2 -phenyl, wherein said phenyl is optionally substituted with halogen, C 1-3 alkyl or C 1-3 haloalkyl; S(O) 0-2 -phenyl, and S(O) 0-2 C 1-3 alkyl;

R b and R b′ are each independently selected from hydrogen, C 1-3 alkyl and C 1-3 haloalkyl;

n is 0, 1, 2, or 3;

R 1 and R 2 are each independently selected from hydrogen, C 1-3 alkyl, C 1-3 haloalkyl or phenyl;

R 3 is hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, C 2-4 hydroxylalkyl, benzyl, wherein the phenyl group of said benzyl is optionally substituted with from 1-3 substituents selected from halogen, C 1-3 alkyl, S(O) 0-2 C 1-3 alkyl, S(O) 0-2 -phenyl, O—C 1-6 alkyl, and OCF 3 ; C(O)—C 1-6 alkyl and C(O)Phenyl;

R 4 is H, C 1-4 alkyl or C 1-4 haloalkyl; or

pharmaceutically acceptable salts thereof.

2. A compound according to claim 1 , wherein:

R x is CN; or

pharmaceutically acceptable salts thereof.

3. A compound according to claim 1 , wherein:

R y is CF 3 or Cl; or

pharmaceutically acceptable salts thereof.

4. A compound according to claim 1 , wherein:

R z is H, CH 3 , CF 3 or Cl; or

pharmaceutically acceptable salts thereof.

5. A compound according to claim 1 , wherein:

R x is CN;

R y is Cl;

R z is CH 3 ; or

pharmaceutically acceptable salts thereof.

6. A compound according to claim 1 , wherein:

A is

 or

pharmaceutically acceptable salts thereof.

7. A compound according to claim 1 , wherein:

R a is OH, CN, OMe, OCF 3 , SO 2 CH 3 , or halogen;

n is 1; or

pharmaceutically acceptable salts thereof.

8. A compound according to claim 1 , wherein:

n is 0; or

pharmaceutically acceptable salts thereof.

9. A compound according to claim 1 , wherein:

R 4 is H, CH 3 or CH 2 CF 3 ; or

pharmaceutically acceptable salts thereof.

10. A compound according to claim 1 , wherein:

R 4 is H; or

pharmaceutically acceptable salts thereof.

11. A compound according to claim 1 , wherein:

R 1 and R 2 are each independently H, CH 3 , or CF 3 , wherein:

at least one of R 1 and R 2 is not H; or

pharmaceutically acceptable salts thereof.

12. A compound according to claim 1 , wherein:

R 1 is H; and

R 2 is CH 3 ; or

pharmaceutically acceptable salts thereof.

13. A compound according to claim 1 , wherein:

R 1 is CH 3 ;

R 2 is H; or

pharmaceutically acceptable salts thereof.

14. A compound according to claim 1 , wherein:

R 1 is H;

R 2 is CF 3 ; or

pharmaceutically acceptable salts thereof.

15. A compound according to claim 1 , wherein:

R 1 is CF 3 ;

R 2 is H; or

pharmaceutically acceptable salts thereof.

16. A compound according to claim 1 , wherein:

R 3 is H; or

pharmaceutically acceptable salts thereof.

17. A compound according to claim 1 , wherein:

R x is CN;

R y is CF 3 or Cl;

R z is CH 3 , C 1 or CF 3 ;

A is

R a is selected from halogen, CN, OCH 3 , or OH;

n is 0 or 1;

R 1 is CH 3 , CF 3 or H;

R 2 is CH 3 , CF 3 or H;

R 3 is H;

R 4 is H, CH 3 , CH 2 CH 3 , or CH 2 CF 3 ; or

pharmaceutically acceptable salts thereof.

18. A compound according to claim 1 , wherein:

R x is CN;

R y is Cl;

R z is CH 3 ;

A is

R a is selected from halogen, CN, OCH 3 or OH;

n is 0 or 1;

R 1 is H or CH 3 ;

R 2 is H or CH 3 ;

R 3 is H;

R 4 is H; and

pharmaceutically acceptable salts thereof; wherein:

at least one of R 1 and R 2 is not H.

19. A compound selected from the following:

2-Chloro-4-((1R,2S)-2-hydroxy-1-(5-phenyl-1,3,4-oxadiazol-2-yl)propylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2S)-2-hydroxy-1-(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)propylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2R)-2-hydroxy-1-(5-phenyl-1,3,4-oxadiazol-2-yl)propylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2S)-1-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2S)-1-(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2S)-2-hydroxy-1-(5-(3-methoxyphenyl)-1,3,4-oxadiazol-2-yl)propylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2S)-2-hydroxy-1-(5-(3-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)propylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2S)-2-hydroxy-1-(5-(4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)propylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2R)-2-hydroxy-1-(5-(3-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)propylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2R)-2-hydroxy-1-(5-(4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)propylamino)-3-methylbenzonitrile,

2-Chloro-3-ethyl-4-((1R,2S)-2-hydroxy-1-(5-phenyl-1,3,4-oxadiazol-2-yl)propylamino)benzonitrile,

2-Chloro-4-((1R,2S)-2-hydroxy-1-(5-phenyl-1,3,4-oxadiazol-2-yl)propylamino)benzonitrile,

4-((1R,2S)-2-Hydroxy-1-(5-phenyl-1,3,4-oxadiazol-2-yl)propylamino)-1-naphthonitrile,

(R)-2-Chloro-4-(2-hydroxy-2-methyl-1-(5-phenyl-1,3,4-oxadiazol-2-yl)propylamino)-3-methylbenzonitrile,

(R)-2-Chloro-4-(1-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxy-2-methylpropylamino)-3-methylbenzonitrile,

4-((1R,2S)-2-Hydroxy-1-(5-phenyl-1,3,4-oxadiazol-2-yl)propylamino)-2-(trifluoromethyl)benzonitrile,

(R)-2-Chloro-4-(2-hydroxy-1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2R)-2-hydroxy-1-(3-phenyl-1,2,4-oxadiazol-5-yl)propylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2R)-1-(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile;

2-Chloro-4-((1R,2R)-1-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2S)-1-(5-(3-chlorophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2S)-1-(5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2R)-1-(5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2S)-2-hydroxy-1-(5-(4-(methylsulfonyl)phenyl)-1,3,4-oxadiazol-2-yl)propylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2R)-2-hydroxy-1-(5-(4-(methylsulfonyl)phenyl)-1,3,4-oxadiazol-2-yl)propylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2R)-2-hydroxy-1-(5-phenyl-1,3,4-thiadiazol-2-yl)propylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2S)-2-hydroxy-1-(5-phenyl-1,3,4-thiadiazol-2-yl)propylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2R)-1-(5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2S)-1-(5-(3-fluoro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2R)-1-(5-(3-chloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile,

4-((1R,2R)-1-(5-(4-Cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methyl-2-(trifluoromethyl)benzonitrile,

2-Chloro-4-((1R,2R)-1-(5-(3,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile,

2,3-Dichloro-4-((1R,2S)-2-hydroxy-1-(5-phenyl-1,3,4-oxadiazol-2-yl)propylamino)benzonitrile,

2,3-Dichloro-4-((1R,2S)-1-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)benzonitrile,

2-Chloro-4-((1R,2R)-1-(5-(2,4-difluorophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2S)-2-hydroxy-1-(5-phenyloxazol-2-yl)propylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2S)-1-(5-(3-chloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile,

Threo-2-chloro-4-(2-hydroxy-2-phenyl-1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2R)-1-(5-(3,4-difluorophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2S)-1-(5-(4-fluoro-3-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2R)-1-(5-(4-fluoro-3-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile,

4-((1R,2S)-1-(5-(4-Cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methyl-2-(trifluoromethyl)benzonitrile,

2-Chloro-4-((1R,2S)-2-hydroxy-1-(5-methyl-1,3,4-oxadiazol-2-yl)propylamino)-3-methylbenzonitrile,

4-((1R,2R)-1-(5-(4-Cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-2-(trifluoro-methyl)benzonitrile,

4-((1R,2S)-1-(5-(4-Cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-2-(trifluoromethyl)benzonitrile,

2-Chloro-4-((1R,2R)-1-(5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-benzonitrile,

2-Chloro-4-((1R,2S)-1-(5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-ethylbenzonitrile,

2-Chloro-4-((1R,2S)-2-hydroxy-1-(5-(4-(methylsulfonyl)phenyl)-1,3,4-oxadiazol-2-yl)propylamino)benzonitrile,

2-Chloro-4-((1R,2S)-2-hydroxy-1-(5-(4-(hydroxymethyl)phenyl)-1,3,4-oxadiazol-2-yl)propylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2S)-1-(5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)benzonitrile,

4-((1R,2R)-1-(5-(4-Cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-1-naphthonitrile,

4-((1R,2R)-2-Hydroxy-1-(5-phenyl-1,3,4-oxadiazol-2-yl)propylamino)-1-naphthonitrile,

4-((1R,2S)-1-(5-(4-(1H-Pyrazol-1-yl)phenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-2-chloro-3-methylbenzonitrile,

2-Chloro-4-((1R,2R)-1-(5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-ethylbenzonitrile,

2-Chloro-4-((1R,2S)-1-(5-(3,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile,

4-((1R,2S)-1-(5-(4-Bromophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-2-chloro-3-methylbenzonitrile,

2-Chloro-4-((1R,2S)-2-hydroxy-1-(5-(4-iodophenyl)-1,3,4-oxadiazol-2-yl)propylamino)-3-methylbenzonitrile,

(R)-2-Chloro-4-(1-(5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxyethylamino)-3-methylbenzonitrile,

4-((1R,2R)-2-Hydroxy-1-(5-(4-(methylsulfonyl)phenyl)-1,3,4-oxadiazol-2-yl)propylamino)-2-(trifluoromethyl)benzonitrile,

4-((1R,2S)-1-(5-(4-Cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)benzo[b]thiophene-7-carbonitrile,

4-((1R,2R)-1-(5-(4-Cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)benzo[b]thiophene-7-carbonitrile,

4-((1R,2S)-1-(5-(4-Fluorophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)benzo[b]thiophene-7-carbonitrile,

4-((1R,2S)-2-Hydroxy-1-(5-phenyl-1,3,4-oxadiazol-2-yl)propylamino)benzo[b]thiophene-7-carbonitrile,

4-((1R,2R)-1-(5-(4-Fluorophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)benzo[b]thiophene-7-carbonitrile,

4-((1R,2R)-2-Hydroxy-1-(5-phenyl-1,3,4-oxadiazol-2-yl)propylamino)benzo[b]thiophene-7-carbonitrile,

5-(5-((1R,2R)-2-(Butyryloxy)-1-(3-chloro-4-cyano-2-methylphenylamino)propyl)-1,3,4-oxa-diazol-2-yl)-2-fluorophenyl butyrate,

4-(5-((1R,2S)-2-(Butyryloxy)-1-(3-chloro-4-cyano-2-methylphenylamino)propyl)-1,3,4-oxa-diazol-2-yl)-2-chlorophenyl butyrate,

2-Chloro-4-((1R,2S)-2-hydroxy-1-(5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)propylamino)-3-methylbenzonitrile,

N-(4-(5-((1R,2R)-1-(3-Chloro-4-cyano-2-methylphenylamino)-2-hydroxypropyl)-1,3,4-oxadiazol-2-yl)phenyl)benzamide,

N-(4-(5-((1R,2R)-1-(3-Chloro-4-cyano-2-methylphenylamino)-2-hydroxypropyl)-1,3,4-oxadiazol-2-yl)phenyl)acetamide,

N-(4-(5-((1R,2R)-1-(3-Chloro-4-cyano-2-methylphenylamino)-2-hydroxypropyl)-1,3,4-oxadiazol-2-yl)phenyl)butyramide,

Sodium 4-(5-((1R,2S)-1-(3-chloro-4-cyano-2-methylphenylamino)-2-hydroxypropyl)-1,3,4-oxadiazol-2-yl)phenyl sulfate,

4-(5-((1R,2S)-2-Acetoxy-1-(3-chloro-4-cyano-2-methylphenylamino)propyl)-1,3,4-oxadiazol-2-yl)phenyl acetate,

4-(5-((1R,2S)-2-(Butyryloxy)-1-(3-chloro-4-cyano-2-methylphenylamino)propyl)-1,3,4-oxadiazol-2-yl)phenyl butyrate,

4-(5-((1R,2S)-2-(Benzoyloxy)-1-(3-chloro-4-cyano-2-methylphenylamino)propyl)-1,3,4-oxadiazol-2-yl)phenyl benzoate,

(1R,2S)-1-(3-Chloro-4-cyano-2-methylphenylamino)-1-(5-phenyl-1,3,4-oxadiazol-2-yl)propan-2-yl acetate,

N-(4-(5-((1R,2S)-1-(3-Chloro-4-cyano-2-methylphenylamino)-2-hydroxypropyl)-1,3,4-oxadiazol-2-yl)phenyl)benzamide,

N-(4-(5-((1R,2S)-1-(3-Chloro-4-cyano-2-methylphenylamino)-2-hydroxypropyl)-1,3,4-oxadiazol-2-yl)phenyl)acetamide,

(R)-2-Chloro-4-(1-(5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl)-3-hydroxypropylamino)-3-methylbenzonitrile,

2-Chloro-4-((1R,2S)-1-(5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-vinylbenzonitrile,

2-Chloro-4-((1R,2S)-1-(5-(3-fluorophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile,

(1R,2S)-1-(3-Chloro-4-cyano-2-methylphenylamino)-1-(5-phenyl-1,3,4-oxadiazol-2-yl)propan-2-yl butyrate, and

(1R,2S)-1-(3-Chloro-4-cyano-2-methylphenylamino)-1-(5-phenyl-1,3,4-oxadiazol-2-yl)propan-2-yl benzoate or a pharmaceutically acceptable salt of any of the foregoing.

20. A pharmaceutical composition comprising a compound according to claim 1 , and at least one pharmaceutically acceptable excipient.

21. A compound represented by formula I

wherein:

R x is CN, Cl, Br, NO 2 or R x1 ;

R y is CH 3 , CF 3 , or halogen;

R z is hydrogen or optionally C 1-3 alkyl, C 2-3 alkenyl, C 1-3 hydroxyalkyl, C 1-3 haloalkyl, NO 2 , NH 2 , OMe, halogen or OH; or

R y and R z together form

wherein R y′ is hydrogen or optionally halogen, C 1-3 alkyl, C 1-3 haloalkyl or OH;

R x1 is a 5 member heteroaryl, said heteroaryl selected from

R′ is hydrogen or optionally C 1 -C 2 alkyl, CF 3 , or halogen; or

R x and R y together with the phenyl group to which they are attached form a 5 member aromatic ring selected from:

wherein each R″ is independently hydrogen or optionally CF 3 , or C 1 -C 2 alkyl;

A is a 5- or 6-member heteroaryl group wherein said 5- or 6-member heteroaryl is substituted with hydrogen and optionally up to two substituents selected from C 1-3 alkyl, CN, C 1-3 haloalkyl or halogen;

B is a phenyl, C 1-6 alkyl, C 1-6 haloalkyl, 5- or 6-member heteroaryl or bicyclic heteroaryl;

each R a is independently selected from C 1-4 alkyl, wherein said C 1-4 alkyl is optionally substituted with from 1-2 substituents independently selected from CN, OH and 5 member heteroaryl; 5-member heteroaryl, CN, —N(R b )C(O)OC 1-6 alkyl, —N(R b )C(O)OPhenyl, wherein said phenyl is optionally substituted with from 1-3 substituents independently selected from CN, halogen, OH, C 1-3 alkyl, and OC 1-3 alkyl; —N(R b )C(O)C 1-6 alkyl, —N(R b )C(O)phenyl, wherein said phenyl is optionally substituted with from 1-3 substituents independently selected from CN, halogen, OH, C 1-3 alkyl, and OC 1-3 alkyl; NR b R b′ , C 1-4 haloalkyl, halogen, OH, OC 1-3 alkyl, OC 1-3 haloalkyl, OC(O)C 1-12 alkyl, OC(O)phenyl, wherein said phenyl is optionally substituted with from 1-3 substituents independently selected from CN, halogen, OH, C 1-3 alkyl, and OC 1-3 alkyl; OC(O)OC 1-12 alkyl, OC(O)Ophenyl, wherein said phenyl is optionally substituted with from 1-3 substituents independently selected from CN, halogen, OH, C 1-3 alkyl, and OC 1-3 alkyl; OSO 2 -phenyl, wherein said phenyl is optionally substituted with halogen, C 1-3 alkyl or C 1-3 haloalkyl; OSO 3 —, OPO 3 —, OSO 2 NR b R b′ , S(O) 0-2 Phenyl, and S(O) 0-2 C 1-3 alkyl;

each R b and R b′ is independently selected from hydrogen, C 1-3 alkyl and C 1-3 haloalkyl;

n is 0, 1, 2, or 3;

n′ is 0 or 1;

n″ is 0 or 1;

each R 1 , R 2 , R 5 , R 6 , R 7 and R 8 are independently selected from hydrogen, C 1-3 alkyl, C 1-3 haloalkyl, OR 3 and phenyl;

R 9 is hydrogen, C 1-3 alkyl or OR 3 , provided that at least one of R 1 , R 2 , R 5 , R 6 , R 7 , R 8 or R 9 is OR 3 ;

each R 3 is independently selected from hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, C 2-4 hydroxylalkyl, benzyl, wherein the phenyl group of said benzyl is optionally substituted with from 1-3 substituents independently selected from halogen, C 1-3 alkyl, S(O) 0-2 C 1-3 alkyl, S(O) 0-2 -phenyl, O—C 1-6 alkyl, and OCF 3 ; C(O)—C 1-10 alkyl, SO 3 —, PO 3 —, SO 2 NR b R b′ , and C(O)phenyl; and

R 4 is H, C 1-4 alkyl or C 1-4 haloalkyl; or

pharmaceutically acceptable salts thereof.